Skip to main content

Table 2 Use of treatments among respondents overall and stratified by mean monthly migraine days (MMDs)

From: My Migraine Voice survey: disease impact on healthcare resource utilization, personal and working life in Finland

  Overall 4 ≤ MMD < 8 8 ≤ MMD < 15 MMD ≥ 15 p-value
N 338 133 139 66  
Use of acute treatment (%) 319 (94.4) 128 (96.2) 129 (92.8) 62 (93.9) 0.455
Currently used acute medication (%)
 Non-opioid pain relievers 254 (80.4) 101 (78.9) 109 (85.8) 44 (72.1) 0.074
 Triptans 256 (81.0) 98 (76.6) 106 (83.5) 52 (85.2) 0.240
 Anti-emetics 112 (35.4) 41 (32.0) 43 (33.9) 28 (45.9) 0.157
 Any other 70 (22.2) 23 (18.0) 25 (19.7) 22 (36.1) 0.014
Currently used acute treatment (%)
 Medicine prescribed by a doctor 311 (97.5) 126 (98.4) 125 (96.9) 60 (96.8) 0.717
 OTC medicine 138 (43.3) 55 (43.0) 60 (46.5) 23 (37.1) 0.468
 Non-medical complementary therapies* 95 (29.8) 37 (28.9) 41 (31.8) 17 (27.4) 0.795
 Any other 45 (14.1) 15 (11.7) 22 (17.1) 8 (12.9) 0.449
Ever received prophylactic prescription (%) 281 (83.1) 103 (77.4) 116 (83.5) 62 (93.9) 0.010
Currently used prophylactic medications (%)
 Beta-blockers 121 (43.1) 49 (47.6) 49 (42.2) 23 (37.1) 0.409
 Anti-epileptics 97 (34.5) 29 (28.2) 47 (40.5) 21 (33.9) 0.157
 Anti-depressants 56 (19.9) 17 (16.5) 24 (20.7) 15 (24.2) 0.471
 Onabotulinum toxin A 43 (15.3) 4 (3.9) 17 (14.7) 22 (35.5) < 0.001
 Any other 78 (27.8) 29 (28.2) 32 (27.6) 17 (27.4) 0.993
Number of prophylactic treatment switches/failures (%)
 Never 63 (22.4) 37 (35.9) 18 (15.5) 8 (12.9) < 0.001
 Once 21 (7.5) 12 (11.7) 5 (4.3) 4 (6.5)
 Twice 29 (10.3) 15 (14.6) 10 (8.6) 4 (6.5)
 3 times 47 (16.7) 13 (12.6) 29 (25.0) 5 (8.1)
 4 times 25 (8.9) 8 (7.8) 9 (7.8) 8 (12.9)
 5 times 20 (7.1) 4 (3.9) 11 (9.5) 5 (8.1)
 6 times or more 76 (27.0) 14 (13.6) 34 (29.3) 28 (45.2)
  1. *Not specified
  2. All variables are presented as absolute number and percentage of respondents
  3. OTC over-the-counter